The UK revocation is a regulatory setback but commercially immaterial given already-negligible UK sales. Monitor whether other health authorities (e.g., FDA) initiate similar benefit-risk reviews, which could pose a more material risk to IXCHIQ's broader commercial prospects.
Price Chart
Executive Summary
Valneva announced that the UK MHRA revoked the marketing authorization for its chikungunya vaccine IXCHIQ following a benefit-risk review by the CHM, based on previous safety data with no new safety signal. The company stated the decision has immaterial financial impact as IXCHIQ had low UK sales and was no longer actively distributed, and it will not appeal. EU, Canada, Brazil, and other market authorizations are unaffected.
Key Facts
- UK MHRA revoked IXCHIQ marketing authorization based on review of previous safety data, not a new safety signal.
- Valneva had not actively distributed IXCHIQ in the UK for several months due to low traveler sales.
- No product remains on the UK market; Valneva expects no product recall expense and only minimal impact on overall sales revenue.
- Valneva decided not to appeal, citing immaterial financial/commercial impact and strategic focus on endemic territories.
- EU (EMA) and Health Canada recently concluded similar safety reviews and maintained IXCHIQ authorizations with updated product information.
- Approximately 187,000 doses of IXCHIQ have been administered globally; over 61,000 people vaccinated in Brazil's pilot campaign with no new safety concerns.
Financial Impact
Minimal — Valneva states the UK revocation has only minimal impact on overall sales revenue; no product recall expense expected.
Risk Factors
- Potential for other regulatory authorities to initiate similar safety reviews, possibly affecting IXCHIQ market access in larger territories.
- Negative perception from UK revocation could dampen traveler vaccination demand in other regions.
- Valneva's decision not to appeal leaves the UK market closed, removing a potential future revenue source.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-065400 |
| Document: a6-kcoverpagetemplate.htm | 0001628280-26-065400 |
| Document: 0001628280-26-065400-index-headers.html | 0001628280-26-065400 |
| Document: 0001628280-26-065400-index.html | 0001628280-26-065400 |
| Document: 0001628280-26-065400.txt | 0001628280-26-065400 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $5.91 | awaiting T+20 | — | $5.57 (−5.75%) |
Oct 8, 2026 19d ago | 6-K | $5.69 | awaiting T+20 | — | $5.57 (−2.11%) |
Jun 17, 2026 19w ago | EFFECT | $5.35 $5.08 | ▼ −5.05% | ▼ −6.36% | $5.57 (+4.11%) |
Jun 5, 2026 20w ago | 6-K | $5.48 $5.40 | ▼ −1.46% | ▼ −3.32% | $5.57 (+1.64%) |
Jun 1, 2026 21w ago | 6-K | $5.95 $5.23 | ▼ −12.10% | ▼ −10.80% | $5.57 (−6.39%) |
May 5, 2026 25w ago | 6-K | $5.29 $5.63 | ▲ +6.43% | ▲ +1.47% | $5.57 (+5.29%) |
Mar 26, 2026 30w ago | 6-K | $6.32 $5.50 | ▼ −12.97% | ▼ −23.64% | $5.57 (−11.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers